BackFirst Wave BioPharma Overview

First Wave BioPharma Receivables

First Wave BioPharma's receivables is $1.9M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.88M

Peer average

Loading

First Wave BioPharma Receivables History

Loading

First Wave BioPharma vs. peers: Receivables Comparison

Loading

First Wave BioPharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

First Wave BioPharma (FWBI) FAQ

First Wave BioPharma (FWBI) currently reports a receivables of $1.9M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore First Wave BioPharma's receivables history and peer comparisons.

First Wave BioPharma's receivables changed from $0 to $1.9M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

First Wave BioPharma reported $1.9M in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for First Wave BioPharma, and consider following FWBI for alerts when major investors trade the stock.

First Wave BioPharma is classified in the Healthcare sector. On receivables, it currently shows $1.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FWBI with unrelated industries.